---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Long-term morbidity"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Long-term morbidity. Topics: Psoriatic arthritis: incidence and risk factors in a prospective cohort; Psoriatic arthritis: pooled prevalence, 266 studies; Psoriatic arthritis: onset after skin disease; Myocardial infarction risk by severity and age; 22 further topics. 26 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Psoriatic arthritis: incidence and risk factors in a prospective cohort

> “The data obtained from the 464 patients who were followed up for 8 years were analyzed. A total of 51 patients developed PsA during the 8 years since enrollment. The annual incidence rate of PsA was 2.7 cases (95% confidence interval 2.1-3.6) per 100 psoriasis patients.”
> “A severe psoriasis phenotype, presence of nail pitting, low level of education, and uveitis are predictive of the development of PsA in patients with psoriasis.”

Source: [Eder et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26555117/)

<a id="topic-2.2.1.7-2"></a>

### Psoriatic arthritis: pooled prevalence, 266 studies

> “A total of 266 studies examining 976,408 patients with psoriasis were included. Overall, the pooled proportion (95% confidence interval [CI]) of PsA among patients with psoriasis was 19.7% (95% CI, 18.5%-20.9%).”
> “The PsA prevalence was 22.7% (95% CI, 20.6%-25.0%) in European patients with psoriasis, 21.5% (95% CI, 15.4%-28.2%) in South American patients with psoriasis, 19.5% (95% CI, 17.1%-22.1%) in North American patients with psoriasis”
> “The incidence of PsA among patients with psoriasis ranged from 0.27 to 2.7 per 100 person-years.”

Source: [Alinaghi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29928910/)

<a id="topic-2.2.1.7-3"></a>

### Psoriatic arthritis: onset after skin disease

> “In most patients, psoriasis precedes joint disease by up to 10 years.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.7-4"></a>

### Myocardial infarction risk by severity and age

> “The incidences per 1000 person-years for control patients and patients with mild and severe psoriasis were 3.58 (95% confidence interval [CI], 3.52-3.65), 4.04 (95% CI, 3.88-4.21), and 5.13 (95% CI, 4.22-6.17), respectively.”
> “For example, for a 30-year-old patient with mild or severe psoriasis, the adjusted RR of having an MI is 1.29 (95% CI, 1.14-1.46) and 3.10 (95% CI, 1.98-4.86), respectively. For a 60-year-old patient with mild or severe psoriasis, the adjusted RR of having an MI is 1.08 (95% CI, 1.03-1.13) and 1.36 (95% CI, 1.13-1.64), respectively.”

Source: [Gelfand et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17032986/)

<a id="topic-2.2.1.7-5"></a>

### Major adverse cardiovascular events: meta-analysis of nine studies

> “Severe psoriasis was associated with a significantly increased risk of cardiovascular mortality (RR, 1.39; 95% CI, 1.11 to 1.74), myocardial infarction (RR, 1.70; 95% CI, 1.32 to 2.18), and stroke (RR, 1.56 95% CI, 1.32 to 1.84).”
> “Based on these risk ratios and the background population event rates, psoriasis is associated with an estimated excess of 11 500 (95% CI, 1169 to 24 407) major adverse cardiovascular events each year.”

Source: [Armstrong et al. (2013c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3647278/)

<a id="topic-2.2.1.7-6"></a>

### Diabetes: prevalence and incidence meta-analysis

> “Among studies assessing the prevalence, psoriasis was associated with an odds ratio (OR) of 1.59 (95% CI, 1.38-1.83) for diabetes. The pooled OR was 1.53 (95% CI, 1.16-2.04) for mild psoriasis and 1.97 (1.48-2.62) for severe psoriasis.”
> “Among studies that assessed incidence, psoriasis was associated with a relative risk of 1.27 (95% CI, 1.16-1.40) for developing diabetes.”

Source: [Armstrong et al. (2013a)](https://pubmed.ncbi.nlm.nih.gov/23407990/)

<a id="topic-2.2.1.7-7"></a>

### Metabolic syndrome: pooled odds ratio and dose-response relationship

> “Based on random-effects modeling of cross-sectional and case-controlled studies, the pooled odds ratio (OR) for metabolic syndrome among patients with psoriasis was 2.26 (95% confidence interval [CI] 1.70-3.01) compared with the general population.”
> “A dose-response relationship was also observed between psoriasis severity and prevalence of metabolic syndrome.”

Source: [Armstrong et al. (2013b)](https://pubmed.ncbi.nlm.nih.gov/23360868/)

<a id="topic-2.2.1.7-8"></a>

### Non-alcoholic fatty liver disease: meta-analysis in chronic plaque psoriasis

> “We identified 15 observational (case–control and cross-sectional) studies for a total of 249,933 patients with psoriasis (49% with NAFLD) and 1,491,402 controls (36% with NAFLD). Psoriasis was associated with prevalent NAFLD (n = 11 studies; pooled random-effects odds ratio [OR] 1.96, 95% CI 1.70–2.26; I2 = 97%, p < 0.01).”

Source: [Bellinato et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9184411/)

<a id="topic-2.2.1.7-9"></a>

### Inflammatory bowel disease: meta-analysis

> “Significant associations were found between psoriasis and Crohn disease (odds ratio, 1.70; 95% CI, 1.20-2.40) and between psoriasis and ulcerative colitis (odds ratio, 1.75; 95% CI, 1.49-2.05). Patients with psoriasis had an increased risk of Crohn disease (risk ratio, 2.53; 95% CI, 1.65-3.89) and ulcerative colitis (risk ratio, 1.71; 95% CI, 1.55-1.89).”

Source: [Fu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583370/)

<a id="topic-2.2.1.7-10"></a>

### Depression: prevalence and odds meta-analysis

> “The prevalence of depressive symptoms was 28% using questionnaires and the prevalence of clinical depression was 12% using International Classification of Diseases codes, 19% using Diagnostic and Statistical Manual of Mental Disorders IV, and 9% for antidepressant use.”
> “Psoriasis patients had significantly more depressive symptoms (SMD 1.16; 95% confidence interval (CI) 0.67-1.66), and population-based studies showed that they were at least one and a half times more likely to experience depression (OR 1.57; 95% CI 1.40-1.76) and used more antidepressants than did controls (OR 4.24, 95% CI 1.53-11.76).”

Source: [Dowlatshahi et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24284419/)

<a id="topic-2.2.1.7-11"></a>

### Comorbidities in moderate-to-severe psoriasis compared with matched controls

> “A total of 5,492 matched pairs of moderate-to-severe PsO patients and controls were selected, with a mean age of 47.6 years and 55.5% of patients being male.”
> “PsA was present among 22.1% of PsO patients. Excluding PsA, the most common comorbidities in PsO patients were related to metabolic syndrome, including hyperlipidemia (33.3% vs. 27.3%, adjusted OR [aOR] = 1.3), hypertension (32.8% vs. 23.5%, aOR = 1.6), and diabetes (15.8% vs. 9.7%, aOR = 1.7). Obesity, another condition related to metabolic syndrome, was observed in 4.8% of PsO patients, compared with 2.3% of controls (aOR = 1.9). Depression and anxiety affected 9.1% and 6.3% PsO patients, respectively (aOR = 1.7 and 1.4).”
> “Additionally, PsO patients had an elevated risk of coronary heart disease (aOR = 1.5), cerebrovascular disease (aOR = 1.7), peripheral vascular disease (aOR = 1.6), skin cancer (aOR = 1.9) including nonmelanoma skin cancer (aOR = 2.1), and lymphoma (aOR = 22.7).”

Source: [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/)

<a id="topic-2.2.1.7-12"></a>

### Cardiometabolic comorbidity rising with severity

> “Individuals with psoriasis are more likely to suffer from obesity, cardiovascular disease, non-alcoholic fatty liver disease, diabetes and metabolic syndrome than the general population, with rates being especially elevated in those with more severe psoriasis.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.7-13"></a>

### Psoriatic arthritis: prevalence of 30% to 33% and onset 10 to 11 years after psoriasis

> “Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30%-33% in psoriatic patients.”
> “Thus, after reviewing the body of evidence, the prevalence of PsA among psoriasis patients is 30%-33%, with an onset time of 10-11 years.”
> “Uncontrolled arthritis causes radiologic signs of joint damage in >50% of patients evaluated in tertiary care rheumatology centers.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-14"></a>

### Psoriatic arthritis: prevalence by psoriasis duration and odds by body surface area involvement

> “The prevalence of PsA increased steadily with disease duration, reaching 20.5% among patients with a 30-year history of psoriasis.”
> “Patients with a higher body surface area (BSA) involvement were more likely to acquire PsA (odds ratio [OR] for 1% increase in BSA 1.020, 95% CI 1.012-1.029, P < .0005).”
> “A study of the prevalence of PsA in the United States in 2005 showed that 11% of psoriasis patients had PsA, with 39% indicating it caused a significant impact on activities of daily living.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-15"></a>

### Coronary artery calcification in moderate-to-severe psoriasis

> “Mansouri et al compared coronary artery calcification in 127 moderate-to-severe psoriasis patients with that in diabetic patients without psoriasis.”
> “The 2 groups had equivalent calcification risk, 3 times higher than a subgroup of normal patients.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-16"></a>

### Stroke: adjusted hazard ratios and excess risk by severity

> “After adjusting for major risk factors for stroke, both mild (adjusted hazard ratio [aHR] 1.06, 95% CI 1.0-1.1) and severe (aHR 1.43, 95% CI 1.1-1.9) psoriasis were independent risk factors for stroke.”
> “The excess risk for stroke attributable to patients with psoriasis with mild and severe disease was 1 in 4115 per year and 1 in 530 per year, respectively.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-17"></a>

### Metabolic syndrome: prevalence in a practice-matched cohort

> “Langan et al compared 4065 patients with psoriasis to 40,650 practice-matched control patients.”
> “In total, 34% of psoriasis patients met the criteria for metabolic syndrome, compared with 26% of the controls (OR 1.50, 95% CI 1.40-1.61).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-18"></a>

### Hypertension and diabetes: prevalence in a German health insurance database

> “In a review of a large health insurance database in Germany, Augustin et al identified 33,981 psoriatic patients from a data set of 1,344,071 patients.”
> “The prevalence of hypertension in this cohort was higher for psoriasis patients (35.6%) than controls (20.6%) (prevalence rate 1.73, 95% CI 1.71-1.76).”
> “In this data set, the prevalence rate of diabetes was higher in patients with psoriasis (12.1%) than controls (6.0%) (prevalence rate ratio 2.02, 95% CI 1.96-2.08).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-19"></a>

### Dyslipidemia: hazard and odds ratios compared with controls

> “In a study designed to assess the risk factors for MI occurring after the diagnosis of psoriasis, Kaye et al compared 44,164 psoriasis patients with 219,784 controls matched by age, sex, and index date.”
> “The psoriasis cohort had a higher risk for hyperlipidemia than the control patients (HR 1.17, 95% CI 1.11-1.23).”
> “The OR for dyslipidemia in psoriasis patients was 4.35 (95% CI 3.73-5.06) versus controls.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-20"></a>

### Depression: likelihood compared with controls

> “In a 2014 systematic review and meta-analysis, psoriatic patients had significantly greater symptoms of depression and were at least 1.5 times more likely to have depression than controls.”
> “The use of antidepressants by psoriatic patients was also increased relative to nonpsoriatic patients.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-21"></a>

### Crohn disease and ulcerative colitis: prevalence compared with matched controls

> “In a retrospective analysis of 33,981 patients with psoriasis compared with 1,310,090 matched controls, the likelihood of Crohn's disease was 0.92% for psoriatic patients versus 0.45% for the control group.”
> “The likelihood of ulcerative colitis was also increased, with a 1.1% risk for psoriasis patients versus 0.56% for the controls (prevalence rate 1.91).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-22"></a>

### Malignancy: nonmelanoma skin cancer, lymphoma, and other cancers

> “Frentz et al studied 6905 psoriasis patients who were hospitalized for their skin disease.”
> “They found an increase in the standard incidence rate (SIR) for nonmelanoma skin cancer (NMSC; SIR 2.46, 95% CI 2.13-2.83) and mycosis fungoides (SIR 15.1, 95% CI 4.1-38).”
> “In a systematic review and meta-analysis of 37 observational studies, there was an increased rate of NMSC, respiratory tract cancer, cancer of the upper aerodigestive tract, urinary tract, and non-Hodgkin lymphoma in psoriasis patients relative to controls.”
> “Thus, there appears to be an increased incidence of certain malignancies in patients with psoriasis, particularly lymphohematopoietic cancers (particularly cutaneous T-cell lymphoma), head and neck cancers, and digestive tract malignancies.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-23"></a>

### Chronic kidney disease: adjusted hazard ratios by severity

> “The aHRs for CKD in the overall, mild, and severe psoriasis groups were 1.05 (95% CI 1.02-1.07), 0.99 (95% CI 0.97-1.02), and 1.93 (95% CI 1.79-2.08), respectively.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-24"></a>

### Obstructive sleep apnea and chronic obstructive pulmonary disease

> “The prevalence of OSA in psoriasis patients was increased compared with those in the control group (2.7% vs 1.5%, P < .001).”
> “The pooled OR of psoriatic patients with COPD versus nonpsoriatic controls was 1.45 (95% CI 1.21-1.73).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-25"></a>

### Nonalcoholic fatty liver disease: prevalence on liver ultrasound

> “The psoriasis group had a significantly higher rate of NAFLD relative to healthy controls (65.6% vs 35%; P < .01).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-26"></a>

### Comorbidity guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation

> “This guideline addresses the management of extracutaneous manifestations of psoriasis in adults, including comorbid conditions, mental health, psychosocial wellness, and quality of life (QoL).”
> “This guideline has been developed in accordance with the American Academy of Dermatology (AAD) and AAD association administrative regulations for evidence-based clinical practice guidelines (May 2014)”
> “Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation and as part of the review process; the National Psoriasis Foundation medical board members provided their feedback.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
